Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study

Eric Van Den Neste, MD PhD, Norbert Schmitz, MD, Nicolas Mounier, MD PhD, Devinder Gill, MB FRCPath FRACP FRCPA, Marek Trneny, MD, PhD, Prof., Noel Milpied, John A. Radford, MD, Nicolas Ketterer, Ofer Shpilberg, MD, Ulrich Dührsen, David Ma, MD, Josette Briere, Catherine Thieblemont, Gilles A. Salles, MD PhD, Craig Moskowitz, MD, Bertran Glass, Christian Gisselbrecht

Blood (2015) 126 (23): 517.

https://doi.org/10.1182/blood.V126.23.517.517

Published: 2015

Journal Articles

Emergence of Fc-Gamma-Riib-Dominance Contributes to Resistance to Therapeutic Antibodies in Patients with Chronic Lymphocytic Leukaemia

Melinda Burgess, Sally Mapp, MBBS, PhD FRACP, FRCPA, Roberta Mazzieri, PhD, Jonathan Ellis, BSc, MSc, PhD, Catherine Cheung, Lynne Chambers, Stephen Mattarollo, BSc, PhD, Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Devinder Gill, MB FRCPath FRACP FRCPA, Nicholas Saunders, BSc, PhD

Blood (2015) 126 (23): 447.

https://doi.org/10.1182/blood.V126.23.447.447

Published: 2015

Journal Articles

Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG)

Blood (2015) 126 (23): 815.

https://doi.org/10.1182/blood.V126.23.815.815

Published: 2015

Journal Articles

Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial

Suneet Sandhu, MBBS, MPH, FRACP, FRCPA, Devinder Gill, MB FRCPath FRACP FRCPA, Paul David Turner, MBBS, FRACP, FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MBBS, FRACP, FRCPA, Leanne Berkahn, MD, David R Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Cecily Forsyth, MBBS, FRACP, FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Rosemary Harrup, MBBS, FRACP, FRCPA, Giles Best, BSc, PhD, Mathias Bressel, MSc, Juliana Di Iulio, BAppSc, PhD, Bryone Jean Kuss, PhD MBBS, FRCPA, FRACP, Stephen Mulligan, MBBS, PhD FRACP, FRCPA

Blood (2015) 126 (23): 5295.

https://doi.org/10.1182/blood.V126.23.5295.5295

Published: 2015

Journal Articles

Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL)

Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA, Devinder Gill, MB, FRCPath, FRACP, FRCPA, Paul Turner, MBBS FRACP FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MB BS, FRACP, FRCPA, Leanne Berkahn, MD, David R Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Cecily J Forsyth, MB BS, FRACP, FRCPA, Gavin Cull, MBBS, DM, FRACP, FRCPA, Rosemary Harrup, MB BS, FRACP, FRCPA, Melanie Sulda, B.Sc, PhD, Giles Best, BSc (Hons), PhD, Mathias Bressel, MSc, Juliana Di Iulio, BAppSc, PhD, Bryone J Kuss, MBBS, PhD FRCPA, FRACP

Blood (2014) 124 (21): 4695.

https://doi.org/10.1182/blood.V124.21.4695.4695

Published: 2014

Journal Articles

A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity

Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA, Devinder Gill, MB, FRCPath, FRACP, FRCPA, Paul Turner, MBBS FRACP FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MB BS FRACP FRCPA, Leanne Berkahn, MD, David Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Cecily J Forsyth, MB BS, FRACP, FRCPA, Gavin Cull, MBBS, DM, FRACP, FRCPA, Rosemary Harrup, MB BS, FRACP, FRCPA, Melanie Sulda, B.Sc, PhD, Giles Best, BSc (Hons), PhD, Mathias Bressel, MSc, Juliana Di Iulio, BAppSc, PhD, Bryone J Kuss, MBBS, PhD FRCPA, FRACP

Blood (2014) 124 (21): 3325.

https://doi.org/10.1182/blood.V124.21.3325.3325

Published: 2014

Journal Articles

Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin Lymphoma

Maher K Gandhi, PhD, FRACP, FRCPath, FRCP, Frank Vari, Phd, Pauline Crooks, Colm Keane, MB BCh BAO MSc MRCPI FRCPath, Jamie P Nourse, PhD, Louise A Seymour, MBBS, FRCPA, David Ritchie, MB, PhD, FRACP, FRCPA, David Gottlieb, MB, PhD, FRCPA, FRACP, Devinder Gill, MB, FRCPath, FRACP, FRCPA, Kimberley Jones, BSc

Blood (2012) 120 (21): 49.

https://doi.org/10.1182/blood.V120.21.49.49

Published: 2012

Journal Articles

Identification of Two Novel Chemokines (CCL2 and CXCL2) in B-Chronic Lymphocytic Leukaemia (B-CLL) and Prolonged Survival of Primary B-CLL Cells in Vitro

Devinder Gill, MB, FRCPath, FRACP, FRCPA, Melinda Burgess, Louise Knop, BSc, Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Nigel McMillan, PhD

Blood (2008) 112 (11): 3157.

https://doi.org/10.1182/blood.V112.11.3157.3157

Published: 2008

Journal Articles

The Addition of Rituximab Eliminates the Negative Prognostic Impact of PMBCL Compared to DLBCL in Young Patients with CD20-Positive Aggressive Lymphomas Receiving a CHOP-Like Chemotherapy: Results of a Subgroup Analysis of the Mabthera International Trial Group (MInT) Study

Marek Trneny, MD, PhD, Michael Rieger, Anders Osterborg, MD, PhD, Ruth Pettengel, Darrell J White, MD, Devinder Gill, MB, FRCPath, FRACP, FRCPA, Jan Walewski, MD, Evelyn Kuhnt, Markus Loeffler, Michael Pfreundschuh, MD, PhD, Anthony D. Ho, M.D., Ph.D.

Blood (2008) 112 (11): 839.

https://doi.org/10.1182/blood.V112.11.839.839

Published: 2008

NARROW

Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study

Emergence of Fc-Gamma-Riib-Dominance Contributes to Resistance to Therapeutic Antibodies in Patients with Chronic Lymphocytic Leukaemia

Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial

Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL)

A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity

Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin Lymphoma

Identification of Two Novel Chemokines (CCL2 and CXCL2) in B-Chronic Lymphocytic Leukaemia (B-CLL) and Prolonged Survival of Primary B-CLL Cells in Vitro

The Addition of Rituximab Eliminates the Negative Prognostic Impact of PMBCL Compared to DLBCL in Young Patients with CD20-Positive Aggressive Lymphomas Receiving a CHOP-Like Chemotherapy: Results of a Subgroup Analysis of the Mabthera International Trial Group (MInT) Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only